A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Waldenström macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an incurable disease, the goals for therapy for WM are to relieve symptoms, slow di...
| Publicado en: | Current Oncology Vol. 29; no. 10; pp. 7122 - 7140 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Oct2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159900826&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 159900826 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Oct2022 vid: 29 iid: 10 pid: 97109 pub: MDPI artinfo: ui: 159900826 10.3390/curroncol29100560 159900826 ppf: 7122 ppct: 18 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia. aug: au: Kaedbey, Rayan Forward, Nicholas Sehn, Laurie H. Shafey, Mona Doucette, Sarah Chen, Christine I. affil: Department of Hematology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada sug: ab: Waldenström macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an incurable disease, the goals for therapy for WM are to relieve symptoms, slow disease progression, prevent organ damage, and maintain quality of life. However, given the rarity of WM, clinical trials comparing treatments for WM are limited and there is no definitive standard of care. The selection of first-line WM therapy is thus based on patient factors, disease characteristics, and drug access, with bendamustine-rituximab and Bruton's tyrosine kinase (BTK) inhibitor therapy considered preferred treatments. Other treatments such as proteasome inhibitor- or purine analogue-based therapy, alternative chemoimmunotherapy, and autologous stem cell transplantation are generally reserved for the relapsed setting but may be used in rare circumstances in earlier lines of therapy. This paper summarizes the efficacy and safety of these WM therapies and discusses considerations for treatment from a Canadian perspective. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|